Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

Biotechnology

Healthcare
$3.14 -0.26%

-$0.02 today

Market cap
$53.94M
Beta
1.49
P/E (TTM)
-3.5
EPS (TTM)
-$1.67
52W Low $3.28High $9.82

Volume 0.10M

Average 0.08M

VRCA Income Before Tax

Profit after all operating and non-operating items but before income tax.

Verrica Pharmaceuticals Inc.NASDAQ: VRCA

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$9.68M, compared with -$9.74M a year earlier. Trailing-twelve-month income before tax was -$17.83M.

Context

  • Income before tax amounted to 50.3% of revenue in FY2025, down 961.9 pp from a year earlier.
  • Income before tax grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$9.68M or moves back toward the trailing-twelve-month quarterly average of -$4.46M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$9.68M-19.9% QoQ
Last fiscal yearDec 2025
-$17.89M+76.6% YoY
LTMMar 2026
-$17.83M+73.0% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.6%——
1 year+76.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(17.89M) USD
Year-over-year change
+76.6%

Income Before Tax vs competitors

How VRCA compares with its peers on the latest reported figures

  • VRCA's LTM Mar 2026 income before tax of -$17.83M is the 3rd highest of the 5 companies compared; the peer median is -$23.66M.
  • Its year-over-year change of +73.0% is the 2nd highest of 5, against a peer median of +44.7%.
  • Income before tax amounts to 48.0% of revenue for VRCA, versus a peer median of 61.9%.
VRCA Competitors Peer median
Income Before Tax for VRCA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
QTTBQ32 Bio Inc.LTM Mar 2026$33.24M +157.0%—61.9%
SABSSAB Biotherapeutics, Inc.LTM Jun 2026-$12.78M +65.5%——
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026-$17.83M +73.0%—48.0%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026-$34.55M +23.8%——
BOLDBoundless Bio, Inc.LTM Mar 2026-$55.99M +14.8%——
Peer median (excluding VRCA) -$23.66M+44.7%—61.9%

Competitors are the stored peer set for VRCA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12M9.03M5.12M7.57M35.58M
Cost of Revenue472K725K746K2.74M3.44M
Gross Profit11.53M8.31M4.38M4.83M32.14M
Gross Margin96.1%92.0%85.4%63.8%90.3%
Research & Development15.93M12.2M20.3M11.84M8.86M
Selling, General & Admin26.98M17.41M47.31M58.82M35.22M
Operating Expenses42.44M29.6M70.14M70.75M44.08M
Depreciation & Amortization472K718K836K1.27M781K
EBITDA(30.31M)(21.6M)(62.2M)(65.9M)(9.36M)
EBITDA Margin-252.6%-239.1%-1213.8%-871.0%-26.3%
Operating Income(30.91M)(21.3M)(65.76M)(65.92M)(11.94M)
Operating Margin-257.6%-235.8%-1283.4%-871.3%-33.6%
Interest Income123K476K2.74M1.42M929K
Interest Expense4.3M2.17M3.96M9.41M7.74M
Other Income / Expenses(4.17M)(3.19M)(1.24M)(10.66M)(5.95M)
Income Before Tax(35.08M)(24.49M)(67M)(76.58M)(17.89M)
Pre-Tax Margin-292.3%-271.1%-1307.5%-1012.1%-50.3%
Income Tax Expense00000
Net Income(35.08M)(24.49M)(67M)(76.58M)(17.89M)
Net Margin-292.3%-271.1%-1307.5%-1012.1%-50.3%
EPS (Basic)(12.97)(7.17)(14.78)(14.78)(1.68)
EPS (Diluted)(12.97)(7.17)(14.78)(14.78)(1.68)
Weighted Avg Shares2.7M3.42M4.53M5.18M10.65M
Weighted Avg Shares (Diluted)2.7M3.42M4.53M5.18M10.65M

Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

Intrinsic Alpha fair value

Locked

Current Price

$3.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.